Abstract:Background Osteoporosis (OP) is a systemic metabolic bone disease characterized by decreased bone mass and destruction of bone microstructure, which tends to result in enhanced bone fragility and related fractures. The postmenopausal osteoporosis (PMOP) has a relatively high proportion, and numerous studies reveal that estrogen-deficiency is related to the imbalance of gut microbiota (GM), impaired intestinal mucosal barrier function and enhanced inflammatory reactivity. However, the underlying mechanisms remain unclear and the existing interventions are also scarce. Methods In this study, we established a mouse model induced by ovariectomy (OVX) and conducted fecal microbiota transplantation (FMT) by gavage every day for 8 weeks. Subsequently, the bone mass and microarchitecture of mice were evaluated by the micro computed tomography (Micro-CT). The intestinal permeability, pro-osteoclastogenic cytokines expression, osteogenic and osteoclastic activities were detected by the immunohistological analysis, histological examination, enzyme-linked immunosorbent assay (ELISA) and western blot analysis accordingly. Additionally, the composition and abundance of GM were assessed by 16S rRNA sequencing and the fecal short chain fatty acids (SCFAs) level was measured by metabolomics. Results Our results demonstrated that FMT inhibited the excessive osteoclastogenesis and prevented the OVX-induced bone loss. Specifically, compared with the OVX group, FMT enhanced the expressions of tight junction proteins (zonula occludens protein 1 (ZO-1) and Occludin) and suppressed the release of pro-osteoclastogenic cytokines (tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)). Furthermore, FMT also optimized the composition and abundance of GM, and increased the fecal SCFAs level (mainly acetic acid and propionic acid). Conclusions Collectively, based on GM-bone axis, FMT prevented the OVX-induced bone loss by correcting the imbalance of GM, improving the SCFAs level, optimizing the intestinal permeability and suppressing the release of pro-osteoclastogenic cytokines, which may be an alternative option to serve as a promising candidate for the prevention and treatment of PMOP in the future. The translational potential of this article This study indicates the ingenious involvement of GM-bone axis in PMOP and the role of FMT in reshaping the status of GM and ameliorating the bone loss in OVX-induced mice. FMT might serve as a promising candidate for the prevention and treatment of PMOP in the future.

Gut microbial community and fecal metabolomic signatures in different types of osteoporosis animal models

Gut microbiota and fecal metabolic signatures in rat models of disuse-induced osteoporosis

Fecal and Serum Metabolomic Signatures and Microbial Community Profiling of Postmenopausal Osteoporosis Mice Model

Perturbations in gut microbiota composition in osteoporosis: a systematic review and meta-analysis

Gut Microbiota Modulates Osteoclast Glutathione Synthesis and Mitochondrial Biogenesis in Mice Subjected to Ovariectomy

Gut microbiota alterations in postmenopausal women with osteoporosis and osteopenia from Shanghai, China

Fecal microbiota transplantation ameliorates bone loss in mice with ovariectomy-induced osteoporosis via modulating gut microbiota and metabolic function

From gut to bone: deciphering the impact of gut microbiota on osteoporosis pathogenesis and management

Gut microbiota and short-chain fatty acids signatures in postmenopausal osteoporosis patients: A retrospective study

The Association between Gut Microbiota and Osteoporosis was Mediated by Amino Acid Metabolism: Multi-omics Integration in a Large Adult Cohort

Characterization of Intestinal Flora in Osteoporosis Patients Based on 16S rDNA Sequencing

Identifying microbial signatures for patients with postmenopausal osteoporosis using gut microbiota analyses and feature selection approaches

Integrative Bone Metabolomics—Lipidomics Strategy for Pathological Mechanism of Postmenopausal Osteoporosis Mouse Model

Gut Microbiota in Primary Osteoporosis: a Systematic Review

Navigating the gut-bone axis: The pivotal role of Coprococcus3 in osteoporosis prevention through Mendelian randomization

Gut microbiota signatures and fecal metabolites in postmenopausal women with osteoporosis

Anti-osteoporotic drugs affect the pathogenesis of gut microbiota and its metabolites: a clinical study

The Association of Gut Microbiota with Osteoporosis is Mediated by Amino Acid Metabolism: Multiomics in a Large Cohort.

The potential of Klebsiella and Escherichia-Shigella and amino acids metabolism to monitor patients with postmenopausal osteoporosis in northwest China

Gut Microbiota and Serum Metabolic Signatures of High-Fat-Induced Bone Loss in Mice

Species-level gut microbiota analysis in ovariectomized osteoporotic rats by Shallow shotgun sequencing